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background: Mitral annular calcification (MAC) is an independent predictor of cardiovascular events and vascular death. Studies have addressed 
the impact of MAC on mitral valve surgery but there is no data on the impact of MAC on outcomes of aortic valve (AV) surgery. Our study aimed to 
determine the impact of MAC on early (<30 days) and late outcomes (1 year) of patients undergoing AV surgery.
methods: Patients ≥ 40 years of age undergoing elective AV replacement between October 2003 and May 2012 were included. Emergent or redo 
AV surgery patients were excluded. Baseline demographics, surgical, laboratory and echocardiographic data were recorded. Severity of MAC was 
graded by two blinded investigators: Calcification < 2 mm - mild, 2-4 mm - moderate, ≥ 4mm - severe. Early outcomes included: 30 day in hospital 
death, stroke and permanent pacemaker after index surgery. Late outcomes were: 1 year mortality, congestive heart failure, permanent pacemaker 
and stroke.
results: 308 patients were included of whom 67% were males. 108 patients had no MAC, 95 -mild MAC, 74 - moderate MAC, 19 - severe MAC. 
There was no significant difference in baseline characteristics, severity of mitral regurgitation, duration of hospital stay or immediate and long term 
outcomes between the two groups. Subgroup analysis excluding mitral valve replacement did not change results.
NO OR MILD MAC
( 203 )
MODERATE & SEVERE MAC
( 105 )
TOTAL
( 308 )
P - VALUE
AGE AT SURGERY 71.2 +/-11.5 76.1+/-10.5
DBM- 2 61 (30%) 32 (31%) 93 (30%) 0.93
HTN 150(73.9%) 77(73.3%) 227(73.7%) 0.91
CAD 103(50.7%) 63(60%) 166(53.9%) 0.12
PRIOR STROKE 22(10.8%) 8(7.6%) 30(9.7%) 0.36
BETA- BLOCKERS 143(70.4%) 64(61%) 207(67.2%) 0.09
ACEI/ARB 91(44.8%) 40(38.1%) 131(42.5%) 0.25
COUMADIN 80(39.4%) 39(37.1%) 119(38.6%) 0.69
STATIN 119(58.6%) 55(52.4%) 174(56.5%) 0.29
ASPIRIN 128(63.1%) 58(55.2%) 186(60.4%) 0.18
*ANY 1 MONTH COMPLICATIONS 84(44.4%) 42(42.4%) 126(43.8%) 0.74
DURATION OF HOSPITAL STAY 10.95 days 11 days 0.98
LONG TERM OUTCOMES
* DEATH WITHIN 12 MONTHS 12(6%) 5(4.9%) 17(5.6%) 0.68
*STROKE F/U 5(2.6%) 3(3.1%) 8(2.8%) 0.93
*PACER LONGTERM 20(10.5%) 16(16%) 36(12.4%) 0.37
*ANY LONG-TERM COMPLICATION 42(22.8%) 24(24.7%) 66(23.5% 0.71
* indicates 2%-6% missing data
conclusion: Presence of MAC did not impact short/long term complications and mortality in patients undergoing AV replacement.
